Beckley Psytech announces USD $18m raise to conduct clinical trials on psychedelic medicine pipeline
December 18, 2020
Beckley Psytech, a psychedelic medicine company with deep ties to the historical Beckley Foundation, has raised USD $18m of new equity funding to develop psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases. New investors including Noetic Psychedelic Fund LP, a leading venture fund specializing in... Read more
Tryp Therapeutics Begins Trading on the Canadian Securities Exchange
December 18, 2020
Ryan Allway December 18th, 2020 Psychedelics, Top News La Jolla, CA – December 18, 2020 – Tryp Therapeutics Inc. (“Tryp” or the “Company”) (CSE: TRYP) is pleased to announce that the Company’s common shares have commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “TRYP” effective December 18, 2020.... Read more
Innovation zahlt sich aus bei Psychedelika
December 18, 2020
Es besteht ein erhebliches Interesse am psychedelischen Bereich und an den vielversprechenden psychedelischen Molekülen für die Behandlung von psychischen Erkrankungen. Geisteskrankheiten sind eine allgegenwärtige menschliche Erfahrung und eine bisher nur unzureichend behandelte medizinische Notwendigkeit. Psychedelika bieten eine Alternative zu unwirksamen Behandlungen, da sie über andere Wirkmechanismen funktionieren. Psychedelische Arzneimittel... Read more
Innovation Pays Off in Psychedelics
December 18, 2020
Ryan Allway December 18th, 2020 App, Exclusive, Psychedelics, Top Story There has been significant interest in the psychedelic space and of the promise psychedelic molecules show in treating mental health conditions. Mental illness is a ubiquitous human experience and an insufficiently addressed medical necessity. Psychedelics offer an alternative to... Read more
CALGARY, AB, December 17, 2020 – MagicMed Industries Inc. (CSE: MGIC reserved) (“MagicMed” or the “Company“) is pleased to announce the closing of its upsized and oversubscribed previously announced private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately $8.1M (the “Offering“). The offering has been upsized from... Read more
Havn Life Sciences Hits Major Milestone with Research Partner, Complex Biotech Discovery Ventures
December 16, 2020
Ryan Allway December 16th, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind, is pleased... Read more
Ryan Allway December 16th, 2020 Psychedelics atai Life Sciences (“atai” or the “Company”), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the appointment of Greg Weaver as Chief Financial Officer (CFO) and Rolando Gutierrez-Esteinou as Chief Medical Officer (CMO). Mr. Weaver... Read more
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Pharmadrug Provides Corporate Update and Balance Sheet Status
December 16, 2020
Toronto, Ontario–(Newsfile Corp. – December 15, 2020) – Pharmadrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“) is pleased to provide an update to the status of its balance sheet following the recent general equity market upswing and the increase in PharmaDrug’s volume and share price appreciation.... Read more
Empower Clinics Announces Receipt of Over $5,500,000 From Exercise of Warrants, Launches New Corporate Website for Future Integrated Healthcare
December 14, 2020
Ryan Allway December 14th, 2020 Psychedelics EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through its clinics, telemedicine platforms and as a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and validating novel COVID-19 testing protocols for CE, FDA and... Read more
